Real-world adherence to oral anticoagulants in atrial fibrillation patients: a study protocol for a systematic review and meta-analysis
Related Experiment Video
Updated: Jan 31, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Clara L Rodríguez-Bernal1,2, Aníbal García-Sempere1,2, Isabel Hurtado1,2
1Health Services Research Unit, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunidad Valenciana (FISABIO), Valencia, Spain.
Insights
This systematic review examines oral anticoagulant (OAC) adherence in atrial fibrillation (AF) patients. It compares adherence across OACs and analyzes biases in real-world studies using pharmacy data.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Atrial fibrillation (AF) is a major cause of stroke.
- Oral anticoagulants (OACs) reduce stroke risk in AF patients.
- Effective OAC treatment requires good patient adherence.
Purpose of the Study:
- To describe secondary adherence to OACs in real-world settings.
- To compare OAC adherence across different medication classes.
- To identify potential biases in OAC adherence studies using observational databases.
Main Methods:
- Systematic review of longitudinal observational studies.
- Searched PubMed, SCOPUS, and Web of Science databases.
- Meta-analysis of studies using proportion of days covered (PDC) or medication possession ratio (MPR).
Main Results:
- The review synthesizes real-world OAC adherence data.
- Identifies factors influencing adherence and potential study biases.
- Provides a comparative overview of adherence across different OACs.
Conclusions:
- Understanding OAC adherence is crucial for stroke prevention in AF.
- Real-world adherence data informs clinical practice and policy.
- Further research should address identified biases in adherence studies.
Introduction:
Atrial fibrillation (AF) is one of the leading causes of cerebrovascular mortality and morbidity. Oral anticoagulants (OACs) have been shown to reduce the incidence of cardioembolic stroke in patients with AF, adherence to treatment being an essential element for their effectiveness. Since the release of the first non-vitamin K antagonist oral anticoagulant, several observational studies have been carried out to estimate OAC adherence in the real world using pharmacy claim databases or AF registers. This systematic review aims to describe secondary adherence to OACs, to compare adherence between OACs and to analyse potential biases in OAC secondary adherence studies using databases.
Methods And Analysis:
We searched on PubMed, SCOPUS and Web of Science databases (completed in 26 September 2018) to identify longitudinal observational studies reporting days' supply adherence measures with OAC in patients with AF from refill databases or AF registers. The main study endpoint will be the percentage of patients exceeding the 80% threshold in proportion of days covered or the medication possession ratio. Two reviewers will independently screen potential studies and will extract data in a structured format. A random-effects meta-analysis will be carried out to pool study estimates. The risk of bias will be assessed using the Newcastle-Ottawa Scale for observational studies and we will also assess some study characteristics that could affect days' supply adherence estimates.
Ethics And Dissemination:
This systematic review using published aggregated data does not require ethics approval according to Spanish law and international regulations. The final results will be published in a peer-review journal and different social stakeholders, non-academic audiences and patients will be incorporated into the diffusion activities.
Prospero Registration Number:
CRD42018095646.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid Fibrils
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Fibril-associated Collagen
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...

